Seeking Alpha

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its...

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials. (previous)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector